Drug Target Review: Pinpointing function in cancer T cells could be new immunotherapy
UC research has found that increasing a certain function in cancer T cells could mean a new therapy
A previously unknown T cell mechanism that could explain the reason behind decreased immune function in cancer patients has been discovered. According to University of Cincinnati researchers, their finding may present a new immunotherapeutic target for patients with head and neck cancers.
The study, led by Laura Conforti and Ameet Chimote, in the Division of Nephrology and Hypertension, UC Department of Internal Medicine, revealed that a reduced interaction between a molecule called calmodulin and the ion channel KCa3.1 in the immune cells of cancer patients plays an important role in the limited function of these cells. The team performed experiments on cytotoxic T cells taken from the blood of patients with head and neck cancer.
Featured photo courtesy of Laura Conforti and Ameet Chimote.
Related Stories
The future, decoded. UC scholars reveal what’s next
May 20, 2026
The University of Cincinnati’s NEXT Innovation Scholars presented Gen Z-fueled insights on possible future trends at the Futures Forum 2026. Here’s what they see ahead.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.